August 7, 2020

The Niche

Knoepfler lab stem cell blog

human gene editing

2 min read

The human embryo CRISPR paper with Shoukhrat Mitalipov as senior author is coming soon. It will reportedly be focused on the use of CRISPR to genetically modify viable human embryos for reversal of a disease-associated mutation. While strangely press already broke early on this paper last week, as much as a week before the paper comes out, and that press suggests very positive data, how clear will that be from the paper itself? Here are some ideas on the big 5 questions (some include …Read More

6 min read

Are designer babies made using CRISPR or other genetic modification technologies closer to reality today? If so, what exactly should we do about it? Researchers can use CRISPR to genetically modify just about any organism or its cells, but targeting humans is the subject of the most intense discussion including using CRISPR in the human germline for heritable “editing” or genetic modification of humans. This could in theory be done via human embryos or human germ cells with mostly existing technology. CRISPR studies on healthy human …Read More

7 min read

Editors note: This is a guest post from Caroline Simons who is attending the two Paris meetings on human gene editing. For more background on those meetings see here. By Caroline Simons There were just over a hundred participants at the workshop organized by the Federation of European Academies of Medicine, the UK Academy of Medical Sciences and the Académie Nationale de Médicine France. That number included experts in the fields of science, medicine, law and bioethics. They came from Europe, the US and …Read More

2 min read

Now we have an interesting panel starting on questions of governance on human gene editing. This will focus on institutional and national levels of governance. Pilar N. Ossorio, University of Wisconsin, Madison, and Morgridge Institute for Research, is introducing the panel. Key question: how should emerging technologies being governed? Jonathan Kimmelman, from McGill, was the first speaker. How do we evaluate risk versus benefit with human genetic modification? Particularly how to answer this question in the context of clinical trials? Benefit should be defined as …Read More